MX2020007225A - Vectores. - Google Patents
Vectores.Info
- Publication number
- MX2020007225A MX2020007225A MX2020007225A MX2020007225A MX2020007225A MX 2020007225 A MX2020007225 A MX 2020007225A MX 2020007225 A MX2020007225 A MX 2020007225A MX 2020007225 A MX2020007225 A MX 2020007225A MX 2020007225 A MX2020007225 A MX 2020007225A
- Authority
- MX
- Mexico
- Prior art keywords
- cell
- marker
- vector
- marker component
- transduced
- Prior art date
Links
- 239000013598 vector Substances 0.000 title abstract 5
- 239000003550 marker Substances 0.000 abstract 6
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 2
- 239000003153 chemical reaction reagent Substances 0.000 abstract 2
- 150000007523 nucleic acids Chemical group 0.000 abstract 2
- 238000000926 separation method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4211—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/40—Systems of functionally co-operating vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/852—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from cytokines; from lymphokines; from interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Radiology & Medical Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1718088.6A GB201718088D0 (en) | 2017-11-01 | 2017-11-01 | Vectors |
| PCT/GB2018/053149 WO2019086865A1 (en) | 2017-11-01 | 2018-10-31 | Vectors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020007225A true MX2020007225A (es) | 2020-09-25 |
Family
ID=60580018
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020007225A MX2020007225A (es) | 2017-11-01 | 2018-10-31 | Vectores. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20210214748A1 (enExample) |
| EP (1) | EP3703713A1 (enExample) |
| JP (1) | JP2021500905A (enExample) |
| KR (1) | KR20200083554A (enExample) |
| CN (1) | CN111278982A (enExample) |
| AU (1) | AU2018361810A1 (enExample) |
| BR (1) | BR112020008771A2 (enExample) |
| CA (1) | CA3080299A1 (enExample) |
| CL (1) | CL2020001135A1 (enExample) |
| GB (1) | GB201718088D0 (enExample) |
| IL (1) | IL274278A (enExample) |
| MX (1) | MX2020007225A (enExample) |
| RU (1) | RU2020117772A (enExample) |
| SG (1) | SG11202003682SA (enExample) |
| WO (1) | WO2019086865A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3737692A4 (en) | 2018-01-09 | 2021-09-29 | Elstar Therapeutics, Inc. | CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES |
| US12152073B2 (en) | 2018-03-14 | 2024-11-26 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| AU2019297451A1 (en) | 2018-07-03 | 2021-01-28 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
| CN119661722A (zh) | 2019-02-21 | 2025-03-21 | 马伦戈治疗公司 | 结合t细胞相关癌细胞的多功能分子及其用途 |
| EP3927747A1 (en) | 2019-02-21 | 2021-12-29 | Marengo Therapeutics, Inc. | Antibody molecules that bind to nkp30 and uses thereof |
| GB2609554B (en) | 2020-01-03 | 2025-08-20 | Marengo Therapeutics Inc | Anti-TCR antibody molecules and uses thereof |
| CN115975945B (zh) * | 2022-10-25 | 2025-10-28 | 苏州大学 | 荧光蛋白mKate2特异性标记的细胞外囊泡及其构建方法及应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE251181T1 (de) * | 1998-07-28 | 2003-10-15 | Micromet Ag | Heterominikörper |
| US8771988B2 (en) * | 2007-10-12 | 2014-07-08 | Hoffmann-La Roche Inc. | Protein expression from multiple nucleic acids |
| GB201501936D0 (en) * | 2015-02-05 | 2015-03-25 | Ucl Business Plc | Signalling system |
| AU2016342041B2 (en) * | 2015-10-23 | 2021-12-02 | Eureka Therapeutics, Inc. | Antibody/T-cell receptor chimeric constructs and uses thereof |
-
2017
- 2017-11-01 GB GBGB1718088.6A patent/GB201718088D0/en not_active Ceased
-
2018
- 2018-10-31 SG SG11202003682SA patent/SG11202003682SA/en unknown
- 2018-10-31 US US16/760,848 patent/US20210214748A1/en not_active Abandoned
- 2018-10-31 JP JP2020524042A patent/JP2021500905A/ja active Pending
- 2018-10-31 CA CA3080299A patent/CA3080299A1/en not_active Abandoned
- 2018-10-31 RU RU2020117772A patent/RU2020117772A/ru unknown
- 2018-10-31 WO PCT/GB2018/053149 patent/WO2019086865A1/en not_active Ceased
- 2018-10-31 AU AU2018361810A patent/AU2018361810A1/en not_active Abandoned
- 2018-10-31 EP EP18800281.0A patent/EP3703713A1/en not_active Withdrawn
- 2018-10-31 CN CN201880070714.6A patent/CN111278982A/zh active Pending
- 2018-10-31 KR KR1020207015705A patent/KR20200083554A/ko not_active Withdrawn
- 2018-10-31 MX MX2020007225A patent/MX2020007225A/es unknown
- 2018-10-31 BR BR112020008771-8A patent/BR112020008771A2/pt not_active Application Discontinuation
-
2020
- 2020-04-27 IL IL274278A patent/IL274278A/en unknown
- 2020-04-29 CL CL2020001135A patent/CL2020001135A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3703713A1 (en) | 2020-09-09 |
| WO2019086865A1 (en) | 2019-05-09 |
| CL2020001135A1 (es) | 2020-09-25 |
| AU2018361810A1 (en) | 2020-05-14 |
| KR20200083554A (ko) | 2020-07-08 |
| CN111278982A (zh) | 2020-06-12 |
| IL274278A (en) | 2020-06-30 |
| RU2020117772A (ru) | 2021-12-02 |
| JP2021500905A (ja) | 2021-01-14 |
| US20210214748A1 (en) | 2021-07-15 |
| SG11202003682SA (en) | 2020-05-28 |
| BR112020008771A2 (pt) | 2020-12-29 |
| GB201718088D0 (en) | 2017-12-13 |
| CA3080299A1 (en) | 2019-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020001135A1 (es) | Vectores. | |
| CL2017002199A1 (es) | Vectores retrovirales a lentivirales | |
| MX2020004578A (es) | Composiciones de casz y metodos de uso. | |
| CL2021000717A1 (es) | Constructos de anticuerpo para cd70 y cd3. divisional de solicitud 270-2018 | |
| AR120511A2 (es) | Producción de proteínas heteromultiméricas | |
| CO2021017650A2 (es) | Vectores víricos y uso de los mismos en terapias celulares adoptivas | |
| CA3081446A1 (en) | Methods and compositions for polypeptide analysis | |
| BR112021026376A2 (pt) | Proteínas de fusão flt3l-fc e métodos de uso | |
| CR20180067A (es) | Constructos de anticuerpo para flt3 y cd3 | |
| MX2019008221A (es) | Anticuerpo anti-gpc3. | |
| MX2017007826A (es) | Proteina de fusion que conprende tres dominios de union a 5t4 y cd3. | |
| MX369149B (es) | Construcciones de anticuerpos para cdh19 y cd3. | |
| AR107444A1 (es) | Composición farmacéutica que comprende constructos de anticuerpo biespecíficos | |
| AR101669A1 (es) | Constructos de anticuerpos para cdh19 y cd3 | |
| MX2018003062A (es) | Receptores de celula t que reconocen kras mutante restringido en hla-cw8. | |
| WO2012019038A3 (en) | Assessing features for classification | |
| AR101400A1 (es) | Constructo de anticuerpo de cadena individual biespecífico con distribución mejorada de tejido | |
| MX2018000845A (es) | Vector vírico orf recombinante. | |
| AR110093A1 (es) | D-psicosa 3-epimerasa y método para preparar d-psicosa utilizando la misma | |
| EA201791610A1 (ru) | Проникающие в клетку антитела | |
| MX371403B (es) | Moleculas de andamiaje a base de fibronectina estabilizada. | |
| AR083497A1 (es) | Kit para detectar el virus de la leucemia bovina (blv), y uso del mismo | |
| PE20190415A1 (es) | Anticuerpos anti-basigin humanizados y uso de los mismos | |
| WO2015134928A3 (en) | Point of care assays to detect the status of tuberculosis infection | |
| BR112016028849A2 (pt) | composição de polietileno para moldagem por injeção |